CLINEXEL Strengthens Leadership with New Senior-Level Appointment

CLINEXEL, a full-service Clinical Research Organization (CRO) known for its high-quality, cost-effective clinical trials across Phases I to IV, has announced a significant addition to its leadership team. Dr. Mukesh Kumar, a renowned expert in clinical research and development, has been appointed as the Chief Scientific Officer (CSO).

With an impressive career spanning global pharmaceutical giants such as Sanofi and Daiichi Sankyo, as well as leading Indian companies like Cipla, Dr. Reddy’s Laboratories, and Lupin, Dr. Kumar brings a wealth of experience to CLINEXEL. His extensive expertise includes clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. He has played a pivotal role in over 100 successful product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.

As CSO, Dr. Kumar will lead all clinical R&D activities and oversee clinical trial operations from Phases I to IV. His focus will be on optimizing clinical strategies, enhancing global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics. His proven track record of implementing cost-effective and innovative clinical trials is expected to add substantial value to CLINEXEL’s clinical programs.

“I am excited to join the experienced and talented team at CLINEXEL. This team has a very successful track record of conducting clinical trials of all phases, for innovative products,” said Dr. Kumar.

Dr. Deepa Arora, CEO of CLINEXEL, expressed her enthusiasm, stating, “I am excited that Dr. Mukesh has decided to join the CLINEXEL team. His appointment underscores our commitment to excellence in clinical trials and clinical development programs by providing best-in-class services and strengthening our position as a trusted partner in the global clinical research landscape.”

About CLINEXEL CLINEXEL is a leading full-service clinical research organization, specializing in executing high-quality, cost-effective clinical trials across Phases I to IV. The company provides comprehensive clinical trial execution and development services for a broad range of product categories, including innovative therapies, 505(b)(2), and repurposed drugs for markets in the USA, EU, and ROW.

For more information, visit www.clinexel.com